#### **1. Company Overview** Laurus Labs Limited (LL) is a research-driven, vertically integrated Indian pharmaceutical and biotechnology company with a global footprint. Founded in 2005, the company has evolved from a niche **anti-retroviral (ARV) API manufacturer** into a leading **full-spectrum pharmaceutical and biotech player**, offering a diversified portfolio across **Generics**, **Contract Development and Manufacturing Organization (CDMO)**, and **Biotechnology**. It serves over **250 global clients**, including 90% of the world’s top pharmaceutical companies, across more than **80 countries**, with 68% of revenue from exports. The company is listed on both the **BSE and NSE** in India and maintains strong ESG credentials, including an MSCI “BBB” rating. --- #### **2. Business Segments & Strategic Diversification** Laurus Labs has **three core business divisions**: 1. **Generics** (API + Finished Dosage Forms - FDF) 2. **CDMO** (Synthesis & Biologics) 3. **Biotechnology** (Laurus Bio, ImmunoACT) | Business Segment | Key Focus | Revenue Growth (Recent) | |------------------|---------|------------------------| | **CDMO** | Small molecule, fermentation, ADCs, peptides, biocatalysis | 28% FY24; 49% FY25 (small molecules) | | **Generics API** | ARV, oncology, cardiovascular, gastroenterology | Stabilizing post 5-year diversification | | **FDF Generics** | Oral solids, ARVs, pediatric formulations | 24% growth FY24 | | **Biotech** | Precision fermentation, CGT (CAR-T), recombinant proteins | 28–90% YoY growth (varies by FY) | - **Strategic Shift**: Over the past five years, Laurus has reduced ARV revenue contribution from **67% to 45%**, while **CDMO grew from 13% to 28%** of total revenue. - Target: Achieve **balanced revenue mix** across CDMO, Generics, and Biotech by 2026. --- #### **3. Key Strengths & Differentiation** - **Global Regulatory Compliance**: Operates **15 D&M sites** approved by **USFDA, EMA, WHO, PMDA, MHRA**, enabling access to stringent markets. - **Vertically Integrated Model**: Full **API-to-FDF control** across most therapeutics, improving quality, speed, and cost efficiency. - **"One Quality Standard for All Markets"**: Ensures uniform global product quality. - **Research-First Philosophy**: Over **2,900 R&D and quality professionals**, including **1,428 R&D scientists**. - **Backward Integration**: Owns intermediates, key starting materials, and fermentation platforms, ensuring supply chain resilience. --- #### **4. Infrastructure & Manufacturing Scale** ##### **Facility Network (India)** | Location | Capabilities | |--------|-------------| | **Visakhapatnam (Vizag)** | 9+ API/DS sites; 8,000+ KL reactor volume; 10+ billion FDF units; CDMO expansion; commercial fermentation (LB-4) under development | | **Hyderabad** | R&D mega-center (200,000 sq. ft at IKP); 48,000 m² R&D infrastructure; CDMO, biotech, CDO development | | **Bangalore** | Microbial fermentation: 240 KL (LB-1, LB-2) | | **Mumbai/Navi Mumbai** | Two GMP cell and gene therapy (CGT) facilities (via **ImmunoACT**) | | **Mysore** | Enzyme and fermentation expansion for bio-manufacturing | - **New Land Allotment**: 532-acre pharmaceutical complex in **Vizag (Andhra Pradesh)** with **$600 million investment planned over 8 years**. - **Total Fermentation Capacity**: - Current: **240 KL** (Bangalore) - Under Development: **+400 KL** (Vizag LB-4) – to begin operations by **end of 2026**. ##### **CDMO R&D & Technology Hubs** - **IKP Knowledge Park (Hyderabad)**: - 200,000 sq. ft advanced R&D center (launched Sept 2024) - Focus: Flow chemistry, high-potency APIs, peptides, ADC payloads, CGTs - Expected to employ **800+ professionals** - **48,000 m² R&D Center**: Houses kilo labs, PD capabilities, sterility labs, formulation development. --- #### **5. Core Therapeutic Areas & Portfolio** | Therapeutic Focus | Key Products/Developments | |-------------------|-------------------------| | **Anti-Retroviral (ARV)** | Global leader in ARV APIs; supplies 80% of tender participants; 25–30% market share in LMICs | | **Oncology** | Leading HPAPI manufacturer in India; expanding into ADCs and targeted therapies | | **Cardiovascular, CNS, Gastroenterology** | Growing generic API & FDF presence | | **Pediatric HIV** | World’s first **ODF (Oral Dispersible Film) formulation** of dolutegravir (pDTG); USFDA approved | | **Cell & Gene Therapy** | NexCAR19 (India’s first indigenous CAR-T) with 73% response rate | | **Animal Health & Crop Science** | 20+ active CDMO projects; JV and MSAs with global agro firms | --- #### **6. CDMO Capabilities & Growth Drivers** - **Integrated CDMO Platform**: - Offers **end-to-end services** from early development to commercial manufacturing (drug substance + product). - Specialized in **complex small molecules**, **HPAPIs**, **peptides**, **biocatalysis**, and **continuous flow chemistry**. - **CDMO Pipeline (Oct 2025)**: - **>110 active projects** - 90+ in **human health** (NCEs, mid-late stage, commercial) - 20+ in **animal health** and **crop science** - **1,428 scientists** dedicated to CDMO development. - **Over 90 DS/DP launches** achieved. - **Technology Platforms**: - **Continuous Flow Chemistry**: Proprietary high-temp/pressure reactors for ton-level production. - **Biocatalysis**: 40% YoY increase in FY24/25 projects; 7+ chemical steps replaced in commercial manufacturing. - **Peptides**: Multiple synthesizers with purification; clinical-to-commercial pipeline expanding. - **High-Potency API (HPAPI)**: Largest dedicated HPAPI manufacturing facility in India. - **ADC Technology**: Acquisition in **antibody-drug conjugates** (payloads and site-specific linkers) to build integrated ADC CDMO offering. --- #### **7. Biotechnology & Innovation Initiatives** ##### **Laurus Bio (Subsidiary)** - **Precision Fermentation**: Produces animal-origin-free recombinant proteins for **pharma, food, vaccines, and cultured meat**. - **Funding**: Received **₹120 crores** from **Eight Roads Ventures and F-Prime Capital** (Dec 2024). - **Investment**: ₹250 crore allocated for **Vizag fermentation site** (Phase 1: 400 KL by 2026). - **Future Goal**: Scale fermentation to **2 million liters** in phases (Greenfield R3 site). ##### **Cell & Gene Therapy – ImmunoACT (Associate)** - **Product**: **NexCAR19** – India’s first indigenous **CAR-T therapy**, approved Oct 2023. - 73% response rate in relapsed/refractory B-cell malignancies - Treated **over 300 patients** across **80+ hospitals** - **Expansion**: - Second GMP facility in **Navi Mumbai (55,000 sq. ft)** – to add **2,500 treatments/year** - Phase 1 of Viral Vector R&D lab (60,000 sq. ft) near completion (FY26) - Laurus holds ~**34% stake**, up from 26% post Phase II trials. ##### **Gene Therapy In-Licensing** - Acquired **4 gene therapy assets from IIT-Kanpur**; advancing into clinical trials. --- #### **8. Joint Ventures & Partnerships** - **KrKA Pharma Private Limited (JV)** - 51:49 joint venture with Slovenian Pharma **KrKA** - Investment: Up to **€50 million** ($54M) over 3 years - Focus: **Highly potent oncology FDF** manufacturing in **Hyderabad** - Output: 150M+ units/year (Phase 1); 10B units total (Phase 2) - Groundbreaking: **June 2025** - Objective: Access **CIS, MENA, Africa, Russia, Latin America** markets - **Strategic Agreements**: - **>10-year contract** with **global animal health leader** for 20+ APIs - **Master Service Agreement (MSA)** with **leading crop science firm** - Partnered with **Willow** for **bio-based steroid and hormone API** routes --- #### **9. Financial & Regulatory Highlights** - **FY2024 Revenue**: ₹5,041 crores (~$605M) - **Gross Margin**: ~52% - **R&D Spend**: 4.3–4.5% of sales (₹68 crore in Q1 FY25) - **Regulatory Filings (Cumulative)**: - **88 DMFs** filed - **342 patents** filed, **184 granted** - In Q1 FY25: **3 approvals received** - **Quality Excellence**: Passed **39 audits (Q1 FY25)** with **no critical findings**; over **130 audits/year** industry-wide. --- #### **10. Capacity Expansion & Capital Expenditure** - **CAPEX Focus**: - Over **80% of capital spend** in **CDMO diversification and capacity expansion** - **$100 million investment** in small molecule R&D and manufacturing infrastructure - **Key Projects**: - **Commercial-scale fermentation facility (Vizag LB-4)**: 400 KL – **2026 operations** - **Animal Health & Crop Protection CDMO sites**: Near-full client commitment - **Unit 2 FDF Capacity**: 10B tablets/capsules (completed brownfield expansion) - **New Dedicated R&D Facilities**: 200,000 sq. ft in Hyderabad; 48,000 m² total R&D footprint --- #### **11. ESG & Sustainability Initiatives** - **Green Technologies**: - **Continuous flow chemistry** – reduces carbon footprint - **100% biomass boiler** under implementation - **Green catalysts**, **enzymatic/biocatalysis**, **SMB chromatography** - **Science-Based Targets (SBTi)**: Committed to **GHG reductions** - **Carbon-Neutral Power** sourcing for selected units.